Onconetix (ONCO) Competitors $0.11 +0.00 (+1.60%) Closing price 04:00 PM EasternExtended Trading$0.11 0.00 (-1.58%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCO vs. LEXX, PLUR, COEP, MRNS, GDTC, CALC, LGVN, EQ, VYNE, and QTTBShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Lexaria Bioscience (LEXX), Pluri (PLUR), Coeptis Therapeutics (COEP), Marinus Pharmaceuticals (MRNS), CytoMed Therapeutics (GDTC), CalciMedica (CALC), Longeveron (LGVN), Equillium (EQ), VYNE Therapeutics (VYNE), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Lexaria Bioscience Pluri Coeptis Therapeutics Marinus Pharmaceuticals CytoMed Therapeutics CalciMedica Longeveron Equillium VYNE Therapeutics Q32 Bio Lexaria Bioscience (NASDAQ:LEXX) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk. Do analysts prefer LEXX or ONCO? Lexaria Bioscience currently has a consensus price target of $7.00, indicating a potential upside of 295.48%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Lexaria Bioscience is more favorable than Onconetix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Onconetix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to LEXX or ONCO? In the previous week, Onconetix had 6 more articles in the media than Lexaria Bioscience. MarketBeat recorded 7 mentions for Onconetix and 1 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 1.87 beat Onconetix's score of 0.17 indicating that Lexaria Bioscience is being referred to more favorably in the media. Company Overall Sentiment Lexaria Bioscience Very Positive Onconetix Neutral Which has more volatility and risk, LEXX or ONCO? Lexaria Bioscience has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.27, meaning that its share price is 227% more volatile than the S&P 500. Which has higher valuation & earnings, LEXX or ONCO? Lexaria Bioscience has higher earnings, but lower revenue than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$496.92K62.52-$5.80M-$0.50-3.54Onconetix$1.87M4.31-$37.41MN/AN/A Is LEXX or ONCO more profitable? Lexaria Bioscience has a net margin of -1,473.04% compared to Onconetix's net margin of -2,758.89%. Onconetix's return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,473.04% -88.88% -83.59% Onconetix -2,758.89%N/A -48.09% Do institutionals and insiders hold more shares of LEXX or ONCO? 13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 26.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 11.4% of Onconetix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer LEXX or ONCO? Lexaria Bioscience received 7 more outperform votes than Onconetix when rated by MarketBeat users. CompanyUnderperformOutperformLexaria BioscienceOutperform Votes7100.00% Underperform VotesNo VotesOnconetixN/AN/A SummaryLexaria Bioscience beats Onconetix on 9 of the 15 factors compared between the two stocks. Remove Ads Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.06M$6.91B$5.63B$8.10BDividend YieldN/A2.73%4.56%4.02%P/E RatioN/A7.2224.5519.02Price / Sales4.31225.58383.6492.49Price / CashN/A65.6738.1634.64Price / Book0.046.506.954.34Net Income-$37.41M$142.41M$3.20B$247.23M7 Day Performance-4.14%-3.10%-2.42%-0.71%1 Month Performance-59.29%-4.64%2.96%-3.92%1 Year Performance-98.09%-8.32%11.14%1.61% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix0.5931 of 5 stars$0.11+1.6%N/A-98.4%$6.95M$1.87M0.0012Short Interest ↑Gap DownHigh Trading VolumeLEXXLexaria Bioscience3.2167 of 5 stars$1.76-0.6%$7.00+297.7%-52.6%$30.89M$496,923.00-3.527Positive NewsPLURPluri1.0194 of 5 stars$4.38-0.5%N/A-46.2%$30.65M$678,000.00-0.78150Short Interest ↓Positive NewsGap DownCOEPCoeptis Therapeutics0.8261 of 5 stars$9.41-0.9%N/A+56.8%$30.51MN/A-1.622Positive NewsMRNSMarinus Pharmaceuticals2.3661 of 5 stars$0.55-0.2%$4.79+771.6%-93.8%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageGDTCCytoMed Therapeutics2.5102 of 5 stars$2.64+1.1%$5.00+89.4%+9.8%$28.88MN/A0.00N/AShort Interest ↓Positive NewsCALCCalciMedica2.4968 of 5 stars$2.08+3.5%$18.00+765.4%-52.5%$28.04MN/A-1.9330Earnings ReportNews CoverageGap UpLGVNLongeveron2.5411 of 5 stars$1.86+0.5%$8.67+365.9%-50.1%$27.77M$2.39M-0.3020Short Interest ↑Gap UpEQEquillium3.4554 of 5 stars$0.82+6.1%$5.00+509.8%-63.2%$27.39M$45.91M-5.8640Earnings ReportNews CoveragePositive NewsGap DownVYNEVYNE Therapeutics2.8791 of 5 stars$1.75+1.7%$6.88+292.9%-39.6%$26.62M$501,000.00-2.0330Short Interest ↑High Trading VolumeQTTBQ32 Bio2.6209 of 5 stars$2.18+5.3%$24.71+1,033.7%N/A$26.59M$-6,651,000.00-0.1539Positive News Remove Ads Related Companies and Tools Related Companies LEXX Alternatives PLUR Alternatives COEP Alternatives MRNS Alternatives GDTC Alternatives CALC Alternatives LGVN Alternatives EQ Alternatives VYNE Alternatives QTTB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCO) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONCO Stock Free ONCO Stock Alerts